Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Psychiatric clinical trials often fail due to poorly managed placebo responses and subjective rating endpoints. Inder Kaul argues that rushing enrollment undermines patient quality. Beyond ticking box-checking eligibility criteria, teams must ensure candidates meet the protocol's clinical intent. Additionally, controlling placebo response demands minimizing unnecessary patient burden, selecting sites carefully, and enforcing strict intra- and inter-rater calibration across trial sites.

Related Insights

In Abivax's trial, placebo patients dropped out due to lack of efficacy, meaning they were monitored for less time than patients on the effective drug. This "adverse event capture" bias can falsely make the drug arm appear to have a higher rate of side effects, a subtle but critical data interpretation error.

There is no inherent conflict between speed and quality. High-quality studies prevent costly setbacks and generate reliable data, ultimately accelerating research programs. A low-quality study is what truly delays timelines by producing unusable or misleading results.

Clinical trial protocols become overly complex because teams copy and paste from previous studies, accumulating unnecessary data points and criteria. Merck advocates for "protocol lean design," which starts from the core research question and rigorously challenges every data collection point to reduce site and patient burden.

While the financial losses from failed trials are staggering, the most devastating outcome is the human cost. Patients, especially those on placebo, invest years of their lives, suffer, and sometimes die while participating in trials that ultimately fail, when they could have been exploring other treatment options.

A common failure in biotech is viewing patients solely as data sources rather than as human partners in the development process. This perspective leads to unnecessarily complex protocols with high patient burden. The most successful firms build relationships with patient advocacy groups and design trials that respect the patient's experience.

Learning from Karuna, Seaport actively combats the high placebo effect in psychiatric trials. Their strategy involves specific design tactics, such as optimizing the frequency of clinician assessments and using a single treatment arm, to minimize both therapeutic interaction and patient expectation bias, which are known drivers of placebo response.

Scientists often design trials to answer every possible academic question, which adds complexity and patient burden. Drug development trials should be ruthlessly focused on two things only: safety and efficacy. All other extraneous research can wait for post-approval studies.

Beyond medical side effects, clinical trials impose a significant 'procedural burden' on patients: frequent travel, extra blood draws, and endless questionnaires. This human cost must be minimized, as it can disrupt a patient's life and limit participation for those without strong support systems.

Many clinical trials fail not because the science is wrong, but because of operational issues like patient recruitment and retention. These problems often stem from overly burdensome and rigid trial designs that deter participation, a preventable error.

Industry leaders often believe their clinical trial designs are patient-centric, but direct experience in community clinics reveals the significant burden placed on patients and caregivers, such as 12-hour blood draw days. This exposure leads to more practical and humane trial designs that improve real-world data collection.